Abstract: A bi-specific chimeric antigen receptor (bi-specific CAR) comprising a single chain variable fragment (scFv) and a single variable domain (VHH) in the extracellular antigen binding domain, wherein the scFv and VHH bind tumor associated antigens. Also provided herein are genetically engineered immune cells expressing such bi-specific CAR and therapeutic uses of the genetically engineered immune cells.
Abstract: A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2) and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).
© 2025 Justia
